# Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

> **NCT04450836** · PHASE2 · TERMINATED · sponsor: **UNICANCER** · enrollment: 234 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Regorafenib then Trifluridine/Tipiracil
- **DRUG:** Trifluridine/Tipiracil then Regorafenib

## Key facts

- **NCT ID:** NCT04450836
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-23
- **Primary completion:** 2024-03-23
- **Final completion:** 2024-12-31
- **Target enrollment:** 234 (ACTUAL)
- **Why stopped:** Following the presentation of the SUNLIGHT study results at ASCO GI and the rapid change in patient management in the majority of centers, the IDMC experts recommended halting inclusion in the SOREGATT study with immediate effect.
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04450836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04450836, "Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04450836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*